Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications

Fineline Cube Aug 4, 2026
Company Drug

Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership

Fineline Cube Aug 4, 2026
Company Drug

Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization

Fineline Cube Aug 4, 2026
Company Drug

Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments

Fineline Cube Aug 23, 2024

Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors

Fineline Cube Aug 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...

Company Drug

Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE

Fineline Cube Aug 23, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...

Company Deals

ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal

Fineline Cube Aug 23, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...

Company Drug

Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease

Fineline Cube Aug 23, 2024

Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301...

Company Drug

Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy

Fineline Cube Aug 23, 2024

Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...

Company

Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers

Fineline Cube Aug 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis

Fineline Cube Aug 23, 2024

Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...

Company Medical Device

Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA

Fineline Cube Aug 23, 2024

Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...

Company Deals

Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights

Fineline Cube Aug 23, 2024

Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals

Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases

Fineline Cube Aug 23, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...

Company Drug

UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection

Fineline Cube Aug 23, 2024

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...

Company

Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability

Fineline Cube Aug 23, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...

Company

3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength

Fineline Cube Aug 23, 2024

3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...

Company

Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy

Fineline Cube Aug 23, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...

Company Drug

Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors

Fineline Cube Aug 23, 2024

Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer

Fineline Cube Aug 23, 2024

Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...

Company Legal / IP

Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion

Fineline Cube Aug 23, 2024

Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...

Company Drug

CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain

Fineline Cube Aug 23, 2024

CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation...

Company Deals

GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets

Fineline Cube Aug 23, 2024

Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...

Posts pagination

1 … 345 346 347 … 702

Recent updates

  • NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications
  • Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership
  • Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization
  • Mabwell (Shanghai) Bioscience Secures NMPA Approval for 9MW5211 Clinical Trials in Primary Biliary Cholangitis
  • Nanjing Leads Biolabs Secures NMPA Approval for Opamtistomig (LBL-024) in Metastatic Colorectal Cancer Clinical Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications

Company Drug

Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership

Company Drug

Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization

Company Drug

Mabwell (Shanghai) Bioscience Secures NMPA Approval for 9MW5211 Clinical Trials in Primary Biliary Cholangitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.